scispace - formally typeset
W

William H. Wunner

Researcher at Wistar Institute

Publications -  71
Citations -  5135

William H. Wunner is an academic researcher from Wistar Institute. The author has contributed to research in topics: Rabies virus & Virus. The author has an hindex of 35, co-authored 71 publications receiving 5028 citations. Previous affiliations of William H. Wunner include Thomas Jefferson University & University of Pennsylvania.

Papers
More filters
Journal ArticleDOI

Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus

TL;DR: It is concluded that arginine-333 is essential for the integrity of an antigenic determinant and for the ability of rabies viruses to produce lethal infection in adult mice.
Journal ArticleDOI

Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.

TL;DR: A plasmid vector, termed pSG5rab.gp, that expresses the rabies virus glycoprotein under the control of an SV40 early promoter, was tested in C3H/He mice for induction of rabie virus-specific immune responses and was fully protected against a subsequent challenge with rabiesirus.
Journal ArticleDOI

Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene

TL;DR: V-RGpro8 virus was highly effective in priming mice to generate a secondary rabies virus-specific cytotoxic T-lymphocyte response following culture of lymphocytes with either ERA or PM strains of rabiesirus.
Journal ArticleDOI

Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine.

TL;DR: This work demonstrates the feasibility of a recombinant virus vaccine containing the rabies glycoprotein gene for immunization of raccoons, and possibly other wildlife, to obtain long-term protection against rabies.
Journal ArticleDOI

Management of Rabies in Humans

TL;DR: No single therapeutic agent is likely to be effective, but a combination of specific therapies could be considered, including rabies vaccine, rabies immunoglobulin, monoclonal antibodies, ribavirin, interferon-alpha, and ketamine.